IRWD Q3 2024 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$92M-19.5% YoY

Gross Profit

$62M67.4% margin

Operating Income

$26M28.0% margin

Net Income

$4M4.0% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

-3.0%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$390M

Total Liabilities

$701M

Stockholders' Equity

-$311M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92M	$114M	-19.5%
Gross Profit	$62M	$113M	-45.5%
Operating Income	$26M	$49M	-47.3%
Net Income	$4M	$15M	-76.2%

Revenue Segments

Royalty

$700,00052%

Collaborative arrangement, collaboration and license agreements

$413,00031%

Collaborative arrangement, other agreements

$222,00017%

Geographic Segments

North America

$89M99%

Europe and Other

$807,0001%